|
Please
download and print the PDF file below:
|
|
|
|
Anndee M. Glick, MPH, MBA, BSN, RN
|
Anndee M. Glick, MPH, MBA, BSN, RN,
is Clinical Nurse, Mercy SafeWatch, St. John’s
Mercy Medical Center, and Graduate Nursing
Student, Barnes-Jewish College of Nursing, St.
Louis, MO.
|
Focal segmental glomerulosclerosis is a form of chronic kidney disease that causes 3.6% of end
stage renal disease cases. While the cause of this disease is multifactoral, the Human Genome
Project has identified some specific chromosome sites linked to this disease process. Treatment
for focal segmental glomerulosclerosis may include corticosteroids, managing hypertension, and
controlling proteinuria. This article discusses the pathophysiology of focal segmental glomerulosclerosis,
treatments, and resources for patient and professional education.
|
|
CE
RELATED INFORMATION |
|
This
offering for 1.4 contact
hours is being provided by
the
American
Nephrology Nurses Association
(ANNA), which
is accredited as a provider
and approver of continuing
education in nursing by
the American Nurses
Credentialing Center-Commission
on Accreditation (ANCCCOA).
This educational activity
is approved by most states
and specialty organizations
that recognize the ANCC-COA
accreditation process. ANNA
is an approved provider of
continuing education in nursing
by the California Board of
Registered Nursing, BRN Provider
No. 00910; and the Kansas
State Board of Nursing, Provider
No. LT0148-0738. This offering
is accepted for RN and LPN
relicensure in Kansas
|
|
|
AUTHOR DISCLOSURE
STATEMENT |
Anndee M. Glick has no conflicts of interest to disclose.
|
ANNA and HDCN CE POLICY STATEMENTS |
The CE policy and disclosure statements of the American Nephrology
Nurses' Association are given in detail on the Symposium
Home Page. The CE policy statements of HDCN are listed on
this page. |